Two	O	0,3
RCTs	B-KP	4,8
[	O	9,10
Wressnigg	O	10,19
et	O	20,22
al	O	23,25
.	O	25,26
,	O	26,27
2014	O	28,32
;	O	32,33
Wressnigg	O	34,43
et	O	44,46
al	O	47,49
.	O	49,50
,	O	50,51
2013	O	52,56
]	O	56,57
assessed	O	58,66
the	O	67,70
immunogenicity	O	71,85
of	O	86,88
a	O	89,90
new	O	91,94
multivalent	B-KP	95,106
vaccine	I-KP	107,114
for	O	115,118
preventing	O	119,129
LD	B-KP	130,132
.	O	132,133
[	O	134,135
Wressnigg	O	135,144
et	O	145,147
al	O	148,150
.	O	150,151
(	O	152,153
2013	O	153,157
)	O	157,158
]	O	158,159
found	O	160,165
that	O	166,170
whilst	O	171,177
all	O	178,181
doses	O	182,187
(	O	188,189
30	O	189,191
,	O	191,192
60	O	193,195
or	O	196,198
90	O	199,201
μg	O	202,204
)	O	204,205
,	O	205,206
given	O	207,212
on	O	213,215
three	O	216,221
occasions	O	222,231
28	O	232,234
days	O	235,239
apart	O	240,245
,	O	245,246
and	O	247,250
formulations	O	251,263
(	O	264,265
with	O	265,269
or	O	270,272
without	O	273,280
an	O	281,283
adjuvant	O	284,292
to	O	293,295
enhance	O	296,303
the	O	304,307
effect13	O	308,316
)	O	316,317
produced	O	318,326
a	O	327,328
positive	O	329,337
response	O	338,346
,	O	346,347
the	O	348,351
90	O	352,354
μg	O	355,357
non-adjuvanted	O	358,372
formulation	O	373,384
produced	O	385,393
the	O	394,397
highest	O	398,405
response	O	406,414
after	O	415,420
the	O	421,424
first	O	425,430
three	O	431,436
vaccinations	O	437,449
.	O	449,450

However	O	451,458
,	O	458,459
after	O	460,465
a	O	466,467
booster	O	468,475
(	O	476,477
9	O	477,478
to	O	479,481
12	O	482,484
months	O	485,491
later	O	492,497
)	O	497,498
,	O	498,499
the	O	500,503
30	O	504,506
μg	O	507,509
adjuvanted	B-KP	510,520
dose	I-KP	521,525
was	O	526,529
most	O	530,534
effective	O	535,544
.	O	544,545
[	O	546,547
Wressnigg	O	547,556
et	O	557,559
al	O	560,562
.	O	562,563
(	O	564,565
2014	O	565,569
)	O	569,570
]	O	570,571
compared	O	572,580
healthy	O	581,588
people	O	589,595
who	O	596,599
were	O	600,604
either	O	605,611
seropositive	O	612,624
[	O	625,626
14	O	626,628
]	O	628,629
or	O	630,632
seronegative	O	633,645
[	O	646,647
15	O	647,649
]	O	649,650
for	O	651,654
LD	O	655,657
.	O	657,658
Participants	O	659,671
received	O	672,680
three	O	681,686
doses	O	687,692
(	O	693,694
30	O	694,696
or	O	697,699
60	O	700,702
μg	O	703,705
of	O	706,708
vaccine	O	709,716
with	O	717,721
aluminium	B-KP	722,731
hydroxide	I-KP	732,741
adjuvant	I-KP	742,750
)	O	750,751
28	O	752,754
days	O	755,759
apart	O	760,765
,	O	765,766
with	O	767,771
a	O	772,773
booster	O	774,781
at	O	782,784
6	O	785,786
months	O	787,793
or	O	794,796
9	O	797,798
to	O	799,801
12	O	802,804
months	O	805,811
.	O	811,812

In	O	813,815
seronegative	B-KP	816,828
people	I-KP	829,835
,	O	835,836
the	O	837,840
antibody	O	841,849
responses	O	850,859
induced	O	860,867
by	O	868,870
the	O	871,874
dose	O	875,879
formulations	O	880,892
were	O	893,897
similar	O	898,905
(p=0.062;	O	906,915
range	O	916,921
for	O	922,925
30	O	926,928
μg	O	929,931
,	O	931,932
3799	O	933,937
to	O	938,940
6937	O	941,945
,	O	945,946
for	O	947,950
60	O	951,953
μg	O	954,956
,	O	956,957
4575	O	958,962
to	O	963,965
8543	O	966,970
)	O	970,971
.	O	971,972

In	O	973,975
seropositive	B-KP	976,988
people	I-KP	989,995
,	O	995,996
the	O	997,1000
60	O	1001,1003
μg	O	1004,1006
dose	O	1007,1011
(	O	1012,1013
range	O	1013,1018
,	O	1018,1019
4895	O	1020,1024
to	O	1025,1027
9435	O	1028,1032
)	O	1032,1033
resulted	O	1034,1042
in	O	1043,1045
significantly	O	1046,1059
higher	O	1060,1066
antibody	O	1067,1075
response	O	1076,1084
than	O	1085,1089
the	O	1090,1093
30	O	1094,1096
μg	O	1097,1099
dose	O	1100,1104
(	O	1105,1106
range	O	1106,1111
,	O	1111,1112
2413	O	1113,1117
to	O	1118,1120
4371	O	1121,1125
;	O	1125,1126
p=0.0001).	O	1127,1137

The	O	1138,1141
booster	O	1142,1149
response	O	1150,1158
was	O	1159,1162
effective	O	1163,1172
at	O	1173,1175
both	O	1176,1180
time	O	1181,1185
points	O	1186,1192
,	O	1192,1193
but	O	1194,1197
more	O	1198,1202
so	O	1203,1205
when	O	1206,1210
administered	O	1211,1223
at	O	1224,1226
9	O	1227,1228
to	O	1229,1231
12	O	1232,1234
months	O	1235,1241
.	O	1241,1242

However	O	1243,1250
,	O	1250,1251
there	O	1252,1257
was	O	1258,1261
a	O	1262,1263
dose	O	1264,1268
effect	O	1269,1275
among	O	1276,1281
seropositive	B-KP	1282,1294
participants	I-KP	1295,1307
favouring	O	1308,1317
the	O	1318,1321
higher	O	1322,1328
(	O	1329,1330
60	O	1330,1332
μg	O	1333,1335
)	O	1335,1336
dose	O	1337,1341
(p=0.0359;	O	1342,1352
for	O	1353,1356
five	O	1357,1361
[	O	1362,1363
16	O	1363,1365
]	O	1365,1366
of	O	1367,1369
the	O	1370,1373
six	O	1374,1377
serotypes	O	1378,1387
,	O	1387,1388
(	O	1389,1390
range	O	1390,1395
28,735	O	1396,1402
to	O	1403,1405
42,381),	O	1406,1414
over	O	1415,1419
the	O	1420,1423
30	O	1424,1426
μg	O	1427,1429
dose	O	1430,1434
(	O	1435,1436
range	O	1436,1441
12,653	O	1442,1448
to	O	1449,1451
17,485).	O	1452,1460

[	O	1461,1462
17	O	1462,1464
]	O	1464,1465
